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In the striatum, the input nucleus of the basal ganglia, the extracellular-signal-regulated
kinase (ERK) pathway, necessary for various forms of behavioral plasticity, is triggered by
the combined engagement of dopamine D1 and ionotropic glutamate receptors. In this
study, we investigated the potential crosstalk between glutamatergic, dopaminergic, and
brain-derived neurotrophic factor (BDNF)-TrkB inputs to ERK cascade by using an ex vivo
model of mouse striatal slices. Our results confirmed that the concomitant stimulation
of D1 and glutamate receptors is necessary to activate ERK in striatal medium spiny
neurons (MSNs). Moreover, we found that ERK activation is significantly enhanced when
BDNF is co-applied either with glutamate or the D1 agonist SKF38393, supporting the
idea of possible integration between BDNF, glutamate, and D1R-mediated signaling.
Interestingly, ERK activation via BDNF-TrkB is upregulated upon blockade of either
AMPAR/NMDAR or D1 receptors, suggesting a negative regulatory action of these
two neurotransmitter systems on BDNF-mediated signaling. However, the observed
enhancement of ERK1/2 phosphorylation does not result in corresponding downstream
signaling changes at the nuclear level. Conversely, the TrkB antagonist cyclotraxin B
partially prevents glutamate- and D1-mediated ERK activation. Altogether, these results
suggest a complex and unexpected interaction among dopaminergic, glutamatergic,
and BDNF receptor systems to modulate the ERK pathway in striatal neurons.
Keywords: striatum, extracellular-signal regulated kinase (ERK), brain-derived neurotrophic factor (BDNF),
dopamine D1 receptors, glutamate receptors
INTRODUCTION
The extracellular-signal regulated kinase (ERK) cascade belongs to the mitogen-activated
protein kinase (MAPK) superfamily, a class of highly conserved serine/threonine
kinases, originally implicated in cell proliferation, survival, and apoptosis (Mebratu
and Tesfaigzi, 2009; Roskoski, 2012). Over the last two decades, considerable attention
has been pointed to the multifaceted role of this signaling cascade in a variety of
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brain functions, from learning and consolidation of long-term
memories to drug addiction and neuropsychiatric disorders
(Mazzucchelli et al., 2002; Trifilieff et al., 2007; Hart and Balleine,
2016; Krawczyk et al., 2016; Borrie et al., 2017; Morè et al., 2020).
In neuronal cells, a variety of extracellular stimuli such
as neurotransmitters, neurotrophic factors, and stressors
can trigger the ERK cascade, ultimately leading to the
phosphorylation of both cytoplasmic and nuclear factors,
including p70 S6 kinase-1 (S6K-1), the MAPK-interacting
serine/threonine kinase 1 (Mnk1) and the transcription
factors cAMP response element-binding factor (CREB) and
Elk-1 (Klann and Dever, 2004; Thomas and Huganir, 2004;
Besnard et al., 2011; Wiegert and Bading, 2011; Roskoski,
2012; Yang et al., 2014). Furthermore, ERK1/2 can regulate
gene transcription by phosphorylating histone H3 on Ser10 via
the kinases MSK-1 and MSK-2 (Brami-Cherrier et al., 2005;
Santini et al., 2007).
In the striatum, the input nucleus of the basal ganglia, the ERK
cascade acts as a coincident detector between the dopaminergic
and glutamatergic pathways. More specifically, glutamate-
induced ERK activation is amplified by D1 receptors stimulation
via cAMP, PKA, and cAMP-regulated phosphoprotein (DARPP-
32) pathway, which maintains ERK1/2 in their active forms
via the concerted inhibitory action of striatal-enriched tyrosine
phosphatase (STEP) and protein phosphatase 1 (PP1; Valjent
et al., 2005; Pascoli et al., 2011). This ERK regulation occurs
in the medium spiny neurons of the direct striatal pathway
(dMSNs), where D1Rs are primarily expressed. The same striatal
pathway is also implicated in the responses to drugs of abuse
such as cocaine and amphetamine (Nestler and Lüscher, 2019).
However, very little is known of the role of ERK signaling
modulation in the medium spiny neuron’s indirect striatal
pathway (iMSNs).
Besides the indirect crosstalk between NMDARs and
dopamine D1 receptors in dMSNs, other studies have found
physical interactions between the C-terminal tails of D1Rs
with GluN1 NMDAR subunit that enable an increased
membrane insertion of D1Rs and are also implicated in the
attenuation of NMDAR-dependent excitotoxicity through a
PI-3 kinase-dependent pathway (Pei et al., 2004; Cahill et al.,
2014a). Also, It has been postulated that the integration of
dopaminergic and glutamatergic stimuli in the direct striatal
pathway occurs via Ras-GRF1 and Ras-GRF2, a family of Ras
exchange factor specifically expressed in the central nervous
system, also necessary for cocaine-induced ERK activation
and long-term behavioral changes (Fasano et al., 2009;
Bernardi et al., 2019).
Moreover, it is well established that the ERK pathway is one
of the molecular effectors of the brain-derived neurotrophic
factor (BDNF). The mature form of BDNF binds to the
tropomyosin receptor kinase B (TrkB), thus activating not
only the Ras-ERK cascade but also the phosphatidylinositol-
3-kinase (PI3 kinase)/Akt and phospholipase Cγ (PLCγ)
pathways. Crucially, BDNF-TrkB mediated signaling has been
linked to synaptogenesis and synaptic plasticity mechanisms
underlying learning and memory (Cunha et al., 2010;
Park and Poo, 2013).
In the striatum, BDNF-TrkB-ERK signaling is believed
to exert a primary pro-survival role for all striatal MSNs,
both belonging to the direct and the indirect pathway
(Nagahara and Tuszynski, 2011; Baydyuk and Xu, 2014).
However, circumstantial evidence has also positively implicated
BDNF-TrkB signaling in behavioral and cellular plasticity
produced by drugs of abuse, including cocaine (McGinty et al.,
2010; Koo et al., 2012; Li et al., 2013) and amphetamine
(McGinty et al., 2011), which both require the concerted action of
dopaminergic and glutamatergic signaling in dMSNs. However,
the crosstalk between dopaminergic/glutamatergic and BDNF
signaling is poorly understood in dMSNs and their effect on ERK
modulation remains to be explored.
Our results, using an ex vivo, adult mouse striatal slice
stimulation system, suggest that a complex integration between
glutamatergic, dopaminergic, and BDNF inputs may occur in
striatal neurons and converges onto the ERK cascade.
MATERIALS AND METHODS
Animals
Two months old C57BL/6 male mice were purchased from
Charles River and housed in a temperature-controlled (21◦C)
environment maintained on a 12-h light–dark cycle. Mice were
given 2–3 days acclimatization period in their holding cages
with food and water available ad libitum before being sacrificed
by cervical dislocation. Animal experiments adhered to the UK
Home Office Animals (Scientific Procedures) Act 1986 and
European Community guidelines (Directive 2010/63/EU) on
animal experimentation. In total, four mice were used for each
dose-response experiment and eight mice were used for each of
the other studies. All experiments were performed in duplicate.
Ex vivo Brain Slices Preparation
Brains slices were prepared as previously described (Cerovic
et al., 2015; Papale et al., 2016). Brains were rapidly removed
from the skull, mounted onto the vibratome stage (Vibratome,
VT1000S-Leica Microsystems), and cut into 200 µm-thick
coronal slices. The slices were taken across the striatum (from
AP = 1.18 mm and AP = 0.02 mm) and randomly assigned to
the different treatments. During the cutting, brains were kept
submerged in ice-cold sucrose-based dissecting solution (87 mM
NaCl, 2.5 mM KCl, 7 mM MgCl2, 1 mM NaH2PO4, 75 mM
sucrose, 25 mM NaHCO3, 10 mM D -glucose, 0.5 mM CaCl2,
2 mM kynurenic acid), oxygenated with 95% O2 and 5% CO2.
Corticostriatal slices were subsequently transferred into a brain
slice chamber (Brain slice chamber-BSC1—Scientific System
Design Inc., Mississauga, ON, Canada) and allowed to recover
for 1 h at 32◦C, with a constant perfusion of carboxygenated
artificial cerebrospinal fluid (ACSF: 124 mM NaCl, 5 mM
KCl, 1.3 mM MgSO47H2O, 1.2 mM NaH2PO4H2O, 2.5 mM
NaHCO3, 10 mM glucose, 2.4 mM CaCl2). SCH233390, CNQX,
AP5, MPEP, LY367385, and cyclotraxin B (Tocris) were applied
to the slices at the doses indicated for 1 h during the recovery
period, whereas SKF38393 (Sigma–Aldrich), BDNF (Tocris), or
glutamate (Sigma–Aldrich) were applied for 10 min after the
recovery period at the doses indicated.
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Following a brief fixation in 4% PFA for 15 min at room
temperature, the slices were rinsed in PBS and cryoprotected in
30% sucrose solution overnight at 4◦C. On the following day,
the slices were further cut into 18 µm-thick sections using a
cryostat (Leica CM1850), mounted onto SuperFrost Plus slides
(Thermo Scientific), and processed for immunohistochemistry
or immunofluorescence.
Immunohistochemistry
Immunohistochemistry was performed as described in Papale
et al. (2016). After quenching with 3% H2O2, 10% methanol
for 15 min, the sections were rinsed in TBS and incubated
for 1 h in blocking solution (5% normal goat serum, 0.1%
Triton X-100). The sections were then incubated overnight at
4◦C with anti-phospho-p44/42 MAP kinase (Thr202/Tyr204;
1:1,000, Cell Signaling Technology, Danvers, MA, USA). On
the following day, a biotinylated goat anti-rabbit secondary
antibody (1:200, Vector Labs) was applied to the sections for
2 h at room temperature. Detection of the bound antibodies was
carried out using a standard peroxidase-based method (ABC-
kit, Vectastain, Vector Labs), followed by incubation with DAB
and H2O2 solution. The sections were subsequently dehydrated
using increasing concentrations of ethanol and mounted with
DPX. Images were acquired from the striatumusing a bright-field
microscope (Leica DMI6000B Macro/Microimaging system)
under a 20× magnification.
Immunofluorescence
Immunofluorescence was performed as described in Papale et al.
(2016). One hour after blocking in 5% normal goat serum and
0.1% Triton X-100 solution, the slices were incubated overnight
at 4◦C with one of the following primary antibodies: anti-
phospho-S6 ribosomal protein (Ser235/236; 1:200, Cell Signaling
Technology, Danvers, MA, USA) or anti-phospho- (Ser10)-
acetylated (Lys14) histone H3 (1:1,000, Millipore, Billerica,
MA, USA) and anti-NeuN (1:1,000, Millipore, Billerica, MA,
USA). The sections were then incubated for 1 h at room
temperature with the following secondary antibodies: AlexaFluor
546 conjugated anti-mouse (1:200, Life Technologies) and
AlexaFluor 488 conjugated anti-rabbit (1:500, Life Technologies).
Single and double-labeled images (1,024 × 1,024 µm) were
obtained at 40× magnification from striatum using a laser
scanning confocal microscopy (Leica SP2) equipped with the
corresponding lasers and appropriate filters sets to avoid the
crosstalk between the fluorochromes.
Image Quantification and Statistics
Neuronal quantification was performed using ImageJ software.
For immunohistochemistry experiments, data are expressed
as the average number of phospho-ERK positive cells counted in
four fields per slice in 2–3 consecutive 18 µm-thick slices (size of
field: 0.036 mm2).
For immunofluorescence experiments, data are presented as
the average number of phospho-S6 or phospho-Ac-H3 positive
cells among NeuN positive cells counted in six fields per slice in
2–3 consecutive 18 µm-thick slices.
Statistical analysis was performed with IBM SPSS Statistics
software (version 25). For dose-response experiments one-way
ANOVAs or Kruskal–Wallis tests were conducted, whereas
two-way ANOVAs were carried out for co-administration of
compounds. For each experimental group, the number of
samples is given by the number of 200 µm-thick slices.
Dose-response curves were generated by GraphPad Prism
software (version 8.3.1). The number of pERK1/2 positive cells
was normalized over not stimulated controls and reported
on Y-axis. The doses of glutamate, SKF38393, and BDNF
are shown on X-axis in a logarithmic (Log10) scale. The
EC50 values were calculated by GraphPad Prism using a
non-linear regression model.
RESULTS
Glutamate, the D1 Receptor Agonist
SKF38393, and BDNF Independently Lead
to a Rapid Dose-Dependent ERK
Phosphorylation in Striatal Slices
Previous work has shown that ERK activation in the striatal
network is a central integration point for ionotropic glutamate
receptors (AMPARs and NMDARs) and dopamine D1 receptors
signaling (Cahill et al., 2014b; Pascoli et al., 2014). However, the
potential interplay between glutamate and dopamine signaling
with BDNF and TrkB receptors in striatal preparations has not
been fully explored. Thus, we sought to carefully investigate
the potential interaction among AMPARs/NMDARs, D1Rs,
and TrkB receptors in a physiological setting consisting of
ex vivo striatal slices preparations from the adult mouse
brain (Cerovic et al., 2015; Papale et al., 2016). This system
is better suited to represent an in vivo situation than
embryonic or early postnatal organotypic cultures and also
allows single-cell analysis which is precluded by standard western
blot analysis.
First, we determined the minimal effective doses of glutamate,
of the selective D1 agonist SKF38393 and of BDNF sufficient
to phosphorylate ERK1/2, the downstream cytoplasmic marker
S6 ribosomal protein, and the nuclear marker histone H3 in
mouse corticostriatal slices. This experiment was important
to demonstrate whether all three stimuli could activate ERK
signaling in the cytoplasm and in the nucleus and to determine
the doses to be used in co-stimulation experiments.
Samples were stimulated for 10 min with increasing
concentrations of glutamate, SKF38393, or BDNF and, after
fixation, were processed for immunohistochemistry to detect
phospho-ERK1/2 positive cells in the striatum. Data indicated
that 5 µM of glutamate (Figure 1A), 5 µM of SKF38393
(Figure 1B), and 2 ng/ml of BDNF (Figure 1C) were sufficient
to induce a significant increase in ERK1/2 activation, whereas
maximal ERK1/2 activation was achieved at 50 µM for all
three stimuli.
Dose-response curves (Figures 1D–F) indicated that the
EC50 was 15.76 µM for glutamate, 20.77 µM for SKF38293,
and 25.21 ng/ml for BDNF. Thus, for further co-stimulation
experiments, we selected sub-optimal doses just below the EC50,
namely 10µM for glutamate, 10µM for SKF38393, and 10 ng/ml
for BDNF.
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FIGURE 1 | (A) Glutamate induces significant extracellular-signal-regulated kinase (ERK) activation at doses ranging from 5 µM to 100 µM (one-way ANOVA,
Welch’s F (6,9.064) = 1,001.854, p < 0.0001. Games Howell’s post hoc: comparisons were made between the not stimulated condition and each glutamate dose:
****p < 0.0001, ***p < 0.001). Data are shown as mean ± SEM, n = 4 per group. Scale bar: 50 µm. (B) SKF38393 activates ERK at doses ranging from 5 µM to
100 µM (one-way ANOVA, F (6,27) = 320.491, p < 0.0001. Bonferroni’s post hoc: comparisons were made between the not stimulated condition and each
SKF38393 dose: ****p < 0.0001, ***p < 0.001). Data are shown as mean ± SEM, n = 4 per group. Scale bar: 50 µm. (C) Brain-derived neurotrophic factor (BDNF)
activates ERK at doses ranging from 2 ng/ml to 100 ng/ml (one-way ANOVA, Welch’s F (7,9.911) = 134.027, p < 0.0001. Games Howell’s post hoc: comparisons were
made between the not stimulated condition and each BDNF dose: ****p < 0.0001, **p < 0.01, *p < 0.05). Data are shown as mean ± SEM, n = 4 per group. Scale
bar: 50 µm. (D–F) Dose-response curves of glutamate, SKF38393, and BDNF on ERK activation. Doses are reported on X-axis in a logarithmic (Log10) scale,
whereas Y-axis shows the number of pERK1/2 positive cells normalized over not stimulated controls. The EC50 values were calculated using GraphPad
Prism software.
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Glutamate, SKF38393, and BDNF Rapidly
Phosphorylate Striatal S6 Ribosomal
Protein and Histone H3 in an
ERK-Dependent Manner
To confirm that all three stimuli were able to activate
downstream signaling to ERK1/2, striatal slices were also
subjected to immunofluorescence analysis to visualize
S6 phosphorylation, assessed at Ser235/236 sites, and histone
H3 phosphorylation at the Ser10 site (and acetylation at Lys14).
Our previous work has shown that those two phosphorylation
sites are entirely ERK1/2 dependent in response to glutamate
and SKF38393 (Papale et al., 2016). However, we never
determined whether BDNF was able to induce S6 and H3 at
those phosphorylation sites.
We found that all three stimuli could activate pS6 and pH3 but
with remarkable differences. In general, higher doses were
required to elicit S6 and H3 phosphorylation than for ERK1/2.
More specifically, 50 µM of glutamate, 50 µM of SKF38393,
and 20 ng/ml of BDNF induced a maximal increase of both
S6 (Figures 2A–C) and H3 phosphorylation (Figures 2D–F),
whereas lower doses failed to elicit a significant activation
of both S6 and H3. Thus, it appears that phosphorylation
of S6 and H3 requires a higher concentration of each
agonist than for ERK1/2 activation and this is possibly
subjected to a threshold effect. Since we were unable to
determine with accuracy an EC50 for either pS6 or pH3, we
focussed exclusively on pERK1/2 analysis in the subsequent
co-stimulation studies.
Co-stimulation With Glutamate and
SKF38393 Enhances ERK1/2 Activation
Early evidence showed that cocaine-induced ERK activation
in vivo in the striatum requires the concomitant stimulation of
D1 and NMDA receptors (Valjent et al., 2005). Also, crosstalk
between D1 and NMDA receptors is necessary to activate
ERK in organotypic slices (Fasano et al., 2009), and that
GluN1 and D1 receptor may physically interact to achieve full
activation of downstream ERK signaling (Pascoli et al., 2011;
Cahill et al., 2014a).
To further confirm and extend these observations in
our ex vivo model, we first assessed the contribution of
NMDA, AMPA, and metabotropic receptors in glutamate-
induced ERK activation. In particular, we focused on the
group I mGluR1 and mGluR5. This class of receptors is
coupled to Gq and, in response to glutamate, stimulates
the phospholipase C pathway. Importantly, mGlu1/5 has
been shown to activate the ERK cascade which in turn
regulates mGluR1/5 signaling and functions (Mao and Wang,
2016). First, we pre-treated the striatal slices for 1 h with
the NMDAR antagonist (2R)-amino-5-phosphonovaleric
acid (AP5, 10 µM), the AMPAR antagonist cyanquixaline
(CNQX, 10 µM), or with a cocktail of mGlu1 and
mGlu5 antagonists, respectively LY367385 (100 µM) and
6-Methyl-2-(phenylethynyl)pyridine hydrochloride (MPEP,
20 µM). Next, we stimulated the slices for 10 min with a
sub-optimal dose of glutamate (10 µM). Interestingly, we
demonstrated that glutamate-induced ERK activation is
completely prevented in the presence of either NMDA, AMPA,
and mGlu1/5 receptors antagonists (Figures 3A–C).
Next, we treated slices with sub-optimal doses of glutamate
(10 µM) and SKF38393 (10 µM), alone or in combination.
As shown in Figures 3D–F, the concomitant stimulation
of glutamate and D1 receptors further enhanced ERK
phosphorylation. The activation is not simply additive but
possibly there is a synergistic component. The co-stimulation
induced a 138% fold increase in ERK activation over glutamate
and SKF38393 alone (Figure 3F).
Moreover, a pre-treatment with the D1 antagonist
SCH23390 (20 µM) significantly attenuated glutamate-induced
ERK1/2 activation, thus indicating that intact D1-mediated
signaling is required for glutamate to trigger ERK signaling
(Figures 3G–I). These data confirmed and extended our
previous data on striatal organotypic cultures which support the
idea that glutamate and D1 receptors interact functionally to
fully induce ERK activation.
BDNF-Mediated ERK Activation Is
Enhanced by a Co-stimulation With Either
SKF38393 or Glutamate
Potential interactions between dopamine D1 receptors and
TrkB receptors or between glutamate receptors and TrkB
receptors have never been investigated in adult striatal systems,
although some aspects of BDNF signaling have been studied
in striatal cultures (Gokce et al., 2009). This is an important
issue since our previous work indicated that BDNF-mediated
ERK activation in striatal organotypic cultures is Ras-GRF1
independent (Fasano et al., 2009). Since Ras-GRF1 is a
crucial, striatal enriched signaling integrator of both NMDARs
and D1Rs on ERK, it is conceivable that BNDF ability
to activate ERK may be independent of the other two
neurotransmitter systems.
Firstly, to determine whether potential crosstalk between
BDNF and D1-mediated signaling exists, striatal slices were
treated with 10 ng/ml BDNF, 10 µM SKF38393 or co-stimulated
with 10 ng/ml BDNF and 10µMSKF38393 for 10min. As shown
in Figures 4A,B, the co-application of BDNF and SKF38393 has
a partial synergistic effect on ERK phosphorylation, with a 138%
fold increase in ERK activation upon co-stimulation over BDNF
and SKF38393 alone (Figure 4C).
Similarly, we sought to determine the potential interaction
between BDNF- and glutamate-mediated signaling by
co-stimulating striatal slices with 10 ng/ml BDNF and
10 µM glutamate for 10 min. Our results demonstrated
that BDNF-mediated ERK phosphorylation is further enhanced
by glutamate (Figures 4D,E). Somewhat, BDNF-glutamate
interactions appeared to be less pronounced, with a 119% fold
increase in ERK activation upon co-stimulation over BDNF and
glutamate alone (Figure 4F).
Altogether, the data indicate that the co-stimulation of
BDNF with the D1R agonist or glutamate may lead to some
functional interactions between the two systems converging on
ERK signaling.
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FIGURE 2 | (A) Glutamate induces phospho-S6 activation at the doses of 50 and 10 µM (one-way ANOVA, Welch’s F F (7,10.078) = 29.488, p < 0.0001. Games
Howell’s post hoc: not stimulated vs. 50 µM ****p < 0.0001, not stimulated vs. 10 µM **p < 0.01). Scale bar: 50 µm. (B) SKF38393 50 µM activates S6
(Kruskal–Wallis test, H(7) = 26.532, p < 0.0001. Pairwise comparisons: not stimulated vs. 50 µM, *p < 0.05). Scale bar: 50 µm. (C) BDNF activates S6 at doses
ranging from 20 ng/ml to 100 ng/ml (one-way ANOVA, F (5,23) = 14.074, p < 0.0001. Bonferroni’s post hoc: not stimulated vs. 100 ng/ml **p < 0.01, not stimulated
vs. 50 ng/ml ****p < 0.0001, not stimulated vs. 20 ng/ml **p < 0.01). Scale bar: 50 µm. (D) Glutamate induces phospho-H3 at doses ranging from 10 to 100 µM
(one-way ANOVA, Welch’s F (7,9.401) = 25.373, p < 0.0001. Bonferroni’s post hoc: comparisons were made between the not stimulated condition and each glutamate
dose: ****p < 0.0001, **p < 0.01). Scale bar: 50 µm. (E) H3 is phosphorylated by SKF38393 50 µM (Kruskal–Wallis test, H(7) = 27.273, p < 0.0001. Pairwise
comparisons: not stimulated vs. 50 µM, *p < 0.05). Scale bar: 50 µm. (F) BDNF activated H3 at doses ranging from 20 to 100 ng/ml. One-way ANOVA,
F (5,23) = 26.854, p < 0.0001. Bonferroni’s post hoc between not stimulated conditions and each BDNF dose: ****p < 0.0001). Scale bar: 50 µm. In all graphs, data
are shown as mean ± SEM, n = 4 per group. In the representative pictures, the red channel (NeuN) is merged with the green channel (phospho-H3 or phospho-S6).
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FIGURE 3 | (A,C) Pre-treatment with AP5 10 µM, CNQX 10 µM or with a mix of MPEP 20 µM and LY367385 100 µM completely prevents glutamate-induced
ERK activation (two-way ANOVA, effect of glutamate F (1,43) = 20.74, p < 0.0001, effect of inhibitors F (3,43) = 28.08, p < 0.0001, effect of interaction F (3,43) = 24.24,
p < 0.0001. Bonferroni’s post hoc, not stimulated vs. glutamate ****p < 0.0001, AP5 + glu vs. glu ****p < 0.0001, CNQX + glu vs. glu ****p < 0.0001, MPEP +
Ly367385 + glu vs. glu ****p < 0.0001). The values of mean, SEM and fold change relative to not stimulated vehicle are shown in panel (C). Data are shown as
mean ± SEM. (B) Representative pictures of anti-phospho-ERK1/2 immunohistochemistry. Scale bar: 50 µm. (D,F) Slices co-stimulated with SKF38393 10 µM and
glutamate 10 µM show increased levels of phospho-ERK1/2 in comparison with those stimulated with SKF38393 10 µM or glutamate 10 µM (two-way ANOVA,
effect of glutamate F (1,24) = 1759.699 p < 0.0001, effect of SKF38393 F (1,24) = 1247.512, p < 0.0001, effect of interaction F (1,24) = 305.606, p < 0.0001.
Bonferroni’s post hoc, not stimulated vs. glutamate: ****p < 0.0001, not stimulated vs. SKF38393: ****p < 0.0001, SKF38393 vs. SKF38393 + glutamate:
####p < 0.0001, glutamate vs. SKF38393 + glutamate: ####p < 0.0001). Data are shown as mean ± SEM. The values of mean, SEM and fold change relative to not
stimulated control are shown in panel (F). Not stimulated: n = 8, glutamate: n = 6, SKF38393: n = 6, SKF38393 + glutamate: n = 8. (E) Representative pictures of
anti-phospho-ERK1/2 immunohistochemistry. Scale bar: 50 µm. (G,I) Pre-treatment with the D1 antagonist SCH23390 20 µM prevents glutamate-induced ERK
(Continued)
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FIGURE 3 | Continued
activation (two-way ANOVA, effect of glutamate F (1,29) = 18.343, p < 0.0001,
effect of SCH23390 F (1,29) = 1.147, p = 0.294, effect of interaction
F (1,29) = 7.342, p = 0.012. Bonferroni’s post hoc, not stimulated vs. glutamate:
****p < 0.0001, glutamate vs. glutamate + SCH23390: *p = 0.016). Data are
shown as mean ± SEM. The values of mean, SEM and fold change relative to
vehicle control are shown in panel (I). Not stimulated: n = 8, SCH23390:
n = 8, glutamate: n = 7, glutamate + SCH23390: n = 7. (H) Representative
pictures of anti-phospho-ERK1/2 immunohistochemistry. Scale bar: 50 µm.
BDNF-Induced ERK Activation Is
Enhanced Upon Either D1R- or
AMPAR/NMDAR-Mediated Signaling
Blockade
To determine whether BDNF-TrkB receptors require either
D1 receptors, glutamate receptors, or both to induce maximal
ERK activation, we pre-treated the slices for 1 h with the D1R
antagonist SCH23390 (20 µM) or with a cocktail of CNQX
(10 µM) and AP5 (10 µM). If ERK activation induced by
BDNF-TrkB receptors is independent of the dopaminergic and
glutamatergic systems, it should also be insensitive to their
receptors blockade.
Surprisingly, we found that upon BDNF stimulation
(10 ng/ml, for 10 min) ERK1/2 phosphorylation was significantly
enhanced in the presence of either AMPAR/NMDAR
(Figures 5A–C) or D1R antagonists (Figures 5G–I). In both
cases, the effect was highly significant, with a 137% and 138%
fold increase in ERK activation upon AMPAR/NMDAR and
D1R blockade, respectively, over BDNF alone (Figures 5C,I).
To verify whether the modulation of BDNF signaling by D1R
and AMPAR/NMDAR results in downstream changes at the
nuclear level, we measured histone H3 phosphorylation upon
BDNF stimulation in the presence of either AMPAR/NMDAR
FIGURE 4 | (A,C) Slices co-stimulated with BDNF 10 ng/ml and SKF38393 10 µM show increased levels of phospho-ERK1/2 (two-way ANOVA, effect of
SKF38393 F (1,26) = 176.023 p < 0.0001, effect of BDNF F (1,26) = 180.356 p < 0.0001, effect of interaction F (1,26) = 38.267 p < 0.0001, Bonferroni’s post hoc: not
stimulated vs. BDNF: ****p < 0.0001, not stimulated vs. SKF38393: ****p < 0.001, SKF38393 vs. BDNF + SKF38393: ####p < 0.0001, BDNF vs. BDNF +
SKF38393: ####p < 0.0001). Data are shown as mean ± SEM. The values of mean, SEM and fold change relative to not stimulated control are shown in panel (C).
Not stimulated: n = 8, SKF38393: n = 7, BDNF: n = 7, BDNF + SKF38393: n = 8. (B) Representative pictures of anti-phospho-ERK1/2 immunohistochemistry. Scale
bar: 50 µm. (D,F) Slices co-stimulated with BDNF 10 ng/ml and glutamate 10 µM show enhanced ERK activation (two-way ANOVA, effect of glutamate
F (1,24) = 154.64 p < 0.0001, effect of BDNF F (1,24) = 116.887 p < 0.0001, effect of interaction F (1,24) = 13.999 p = 0.001. Bonferroni’s post hoc, not stimulated vs.
BDNF: ****p < 0.0001, not stimulated vs. glutamate: ****p < 0.001, glutamate vs. BDNF + glutamate: ####p < 0.0001, BDNF vs. BDNF + glutamate:
####p < 0.0001). Data are shown as mean ± SEM. The values of mean, SEM and fold change relative to vehicle control are shown in panel (F). Not stimulated :
n = 8, glutamate: n = 6, BDNF: n = 6, glutamate + BDNF: n = 8. (E) Representative pictures of anti-phospho-ERK1/2 immunohistochemistry. Scale bar: 50 µm.
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FIGURE 5 | (A,C) Pre-treatment with glutamate antagonists CNQX 10 µM and AP5 10 µM increases BDNF-induced ERK activation (two-way ANOVA, effect of
BDNF F (1,28) = 341.384, p < 0.0001, effect of AP5/CNQX F (1,28) = 19.969, p < 0.0001, effect of interaction F (1,28) = 13.553, p = 0.001. Bonferroni’s post hoc, not
stimulated vs. BDNF: ****p < 0.0001, BDNF vs. BDNF + AP5 + CNQX: ****p < 0.0001). Data are shown as mean ± SEM, n = 8 per group. The values of mean, SEM
and fold change relative to not stimulated control are shown in panel (C). (B) Representative pictures of anti-phospho-ERK1/2 immunohistochemistry. Scale bar:
50 µm. (D,F) Pre-treatment with glutamate antagonists CNQX 10 µM and AP5 10 µM has no effect on BDNF-induced H3 activation (two-way ANOVA, effect of
BDNF F (1,23) = 50.80, p < 0.0001, effect of AP5/CNQX F (1,23) = 1.272, p = 0.2710, effect of interaction F (1,23) = 1.279, p = 0.2697. Bonferroni’s post hoc, not
stimulated vs. BDNF ***p = 0.0007, AP5 + CNQX vs. BDNF + AP5 + CNQX ****p < 0.0001, BDNF vs. BDNF + AP5 + CNQX p = 0.2082). Data are shown as
mean ± SEM. Not stimulated and AP5 + CNQX: n = 6 per group, BDNF: n = 7, BDNF + AP5 + CNQX: n = 8. The values of mean, SEM, and fold change relative to
(Continued)
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FIGURE 5 | Continued
not stimulated vehicles are shown in panel (F); n.s.: not significant. (E)
Representative pictures of phospho-H3 immunofluorescence, where the red
channel (NeuN) is merged with the green channel (phospho-H3). Scale bar:
50 µm. (G,I) Pre-treatment with D1-antagonist SCH23390 upregulates
BDNF-induced ERK phosphorylation (two-way ANOVA, effect of BDNF
F (1,28) = 331.98, p < 0.0001, effect of SCH23390 F (1,28) = 31.82, p < 0.0001,
effect of interaction F (1,28) = 15.51, p = 0.0005. Bonferroni’s post hoc, not
stimulated vs. BDNF ***p < 0.001, BDNF vs. BDNF + SCH23390
***p < 0.001). Data are shown as mean ± SEM, n = 8 per group. The values
of mean, SEM, and fold change relative to not stimulated control are shown in
panel (I). (H) Representative pictures of
anti-phospho-ERK1/2 immunohistochemistry. Scale bar: 50 µm. (J,L)
Pre-treatment with D1-antagonist SCH23390 does not affect BDNF-induced
H3 phosphorylation (two-way ANOVA, effect of BDNF F (1,28) = 76.97,
p < 0.0001, effect of SCH23390 F (1,28) = 0.8778, p = 0.3568, effect of
interaction F (1,28) = 0.01749, p = 0.8957. Bonferroni’s post hoc, not
stimulated vs. BDNF ****p < 0.0001, SCH23390 vs. BDNF + SCH23390
****p < 0.0001, BDNF vs. BDNF + SCH23390 p > 0.9999). Data are shown
as mean ± SEM, n = 8 per group. The values of mean, SEM, and fold change
relative to not stimulated vehicles are shown in panel (L); n.s.: not significant.
(K) Representative pictures of phospho-H3 immunofluorescence, where the
red channel (NeuN) is merged with the green channel (phospho-H3). Scale
bar: 50 µm.
and D1R antagonists. Since we previously found that BDNF
at a dose of 10 ng/ml used for the previous co-stimulation
studies was insufficient to activate histone H3 (Figure 2F), in
the present experiment we stimulated slices with BDNF 20 ng/ml
which significantly enhances pH3.We found that BDNF-induced
histone H3 phosphorylation was not further upregulated
by either AMPA/NMDA (Figures 5D–F) or D1 receptors
blockade (Figures 5J–L).
Overall, these data revealed an unexpected complexity
of the modulation of BDNF-TrkB-ERK signaling by
AMPARs/NMDARs and D1 receptors.
Pre-treatment With TrkB Antagonist
Cyclotraxin B Reduces Glutamate- and
SKF38393-Induced ERK Activation
TrkB-mediated ERK activation depends on the simultaneous
engagement of D1 and glutamatergic systems, suggesting a
competition between BDNF-TrkB on one side and glutamate
and D1 receptors on the other. In principle, such interaction
should be reciprocal, i.e., TrkB receptor blockade should
facilitate glutamate and D1 receptors positive modulation on
ERK activity.
To investigate this point, striatal slices were pre-treated
for 1 h with 1 µM cyclotraxin B, a TrkB receptor antagonist,
and then stimulated for 10 min with 10 µM glutamate or
10 µM SKF38393. As shown in Figure 6, both glutamate- and
SKF38393-induced ERK phosphorylation was significantly
downregulated, albeit not completely inhibited, upon
TrkB blockade.
This result may suggest that BDNF-TrkB signaling is required
for both NMDA/AMPA and D1 receptors to maximally induce
ERK activation. However, this relationship is not reciprocal since
BDNF-induced ERK activation is facilitated by the blockade of
either D1 or NMDA/AMPA receptors.
DISCUSSION
In the present study, we preliminarily investigated the potential
crosstalk between glutamatergic, dopaminergic, and BDNF
inputs to ERK cascade in mouse striatal slices obtained from
mature mouse brains. This approach allowed us to monitor ERK
activation at the single-cell definition in a more physiological
setting in comparison to other traditional techniques used to
study signal transduction, such as the dissociated neuronal
cultures and organotypic slices.
In recent years, the interplay between NMDARs and
dopamine receptors has been extensively studied, given
its essential physiological role but also its involvement in
pathological conditions. It is now known that the ERK cascade
is a common downstream target of glutamate and dopamine
pathways in different brain regions, since its triggering requires
both calcium influx from AMPAR/NMDAR and D1 receptors,
but does not involve D2 receptors activation (Valjent et al.,
2005; Kaphzan et al., 2006; Bertran-Gonzalez et al., 2008). Also,
both NMDAR/AMPAR and D1R are potently activated during
rewarding experience associated with addictive drugs and the
signaling integration originated from these two neurotransmitter
systems modulates the enduring synaptic changes underlying
addictive behavior (Cahill et al., 2014b; Pascoli et al., 2014).
Our results, in agreement with previous findings obtained
in organotypic slices (Fasano et al., 2009), further confirm that
the combined stimulation of glutamate and D1 receptors has a
synergistic effect on ERK phosphorylation. Also, we show that
an intact D1R- mediated signaling is necessary for glutamate to
activate ERK.
Interestingly, our study also suggests synergistic crosstalk
between D1R- and BDNF-mediated signaling onto the ERK
pathway. Previous work already indicated a link between
D1 receptor-mediated activation of TrkB receptors and increased
BDNF expression in striatal cultures. For instance, Iwakura
et al. (2008) demonstrated that SKF39393 can transactivate TrkB
receptors in striatal neurons and this action is accompanied by
the phosphorylation of PLCΥ), Akt, and ERK. These findings
were further extended by Williams and Undieh (2009) who
showed that SKF38393, but not the D2 agonist quinpirole,
increased BDNF protein expression in rat hippocampal and
striatal slices. However, those studies cannot be directly
reconciled with our findings. First of all, Iwakura et al. (2008)
showed a D1R-mediated effect on the TrkB receptor after
3 h, while our study was limited to a short-term (10 min)
effect. Similarly, Williams and Undieh (2009) showed an
increased effect of SKF38393 on BDNF expression after 24 h
treatment. More importantly, our data in Figure 5 indicate
that BDNF-TrkB modulation of ERK signaling is constrained
by D1R (and glutamate receptors) rather than enhanced. It is
formally possible that this short-term inhibitory effect may mask
a long-term positive modulation. However, our observation does
represent the immediate biochemical interplay between BDNF
and dopamine in striatal cells and should deserve some attention.
Importantly, the modulatory effect of D1 receptors on
BDNF-TrkB-ERK could also be replicated with glutamate.
In the presence of AMPAR and NMDAR antagonists, ERK
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FIGURE 6 | (A,C) Glutamate-induced ERK phosphorylation is significantly reduced by the pre-treatment with TrkB antagonist cyclotraxin B (two-way ANOVA, the
effect of glutamate F (1,28) = 135.165, p < 0.0001, the effect of cyclotraxin B F (1,28) = 7.40, p = 0.0111, the effect of interaction F (1,28) = 4.584, p = 0.04. Bonferroni’s
post hoc, not stimulated vs. glutamate: ****p < 0.0001, glutamate vs. glutamate + cyclotraxin B: **p = 0.002). Data are shown as mean ± SEM, n = 8 per group. The
values of mean, SEM, and fold change relative to vehicle are shown in panel (C). (B) Representative pictures of anti-phospho-ERK1/2 immunohistochemistry. Scale
bar: 50 µm. (D,F) Pre-treatment with cyclotraxin B downregulates SKF38393-induced ERK activation (two-way ANOVA, effect of SKF38393 F (1,27) = 55.030,
p < 0.0001, effect of cyclotraxin B F (1,27) = 4.947, p = 0.035, effect of interaction F (1,27) = 1.99, p = 0.17. Bonferroni’s post hoc, not stimulated vs. SKF38393
****p < 0.0001, SKF38393 vs. SKF38393 + cyclotraxin B *p = 0.014). Data are shown as mean ± SEM. The values of mean, SEM, and fold change relative to not
stimulated control are shown in panel (F). Not stimulated: n = 8, cyclotraxin B: n = 7, SKF38393: n = 8, SKF38393 + cyclotraxin B: n = 8. (E) Representative pictures
of anti-phospho-ERK1/2 immunohistochemistry. Scale bars: 50 µm.
phosphorylation is significantly enhanced in response to BDNF
(see Figure 5). This is not entirely surprising since substantial
evidence indicated that NMDARs and D1Rs do positively
interact in striatal cells to stimulate ERK, also through
physical interactions via GluN1 subunits and D1R-mediated
phosphorylation of GluN2B (Pascoli et al., 2011; Cahill et al.,
2014a). In that respect, D1Rs and NMDARs can be seen as an
integrated system within striatal medium spiny neurons of the
direct pathway able to activate the associated circuitry.
Also, our data show that the observed increase in ERK
activation in response to the co-application of BDNF and
either AMPAR/NMDAR and D1 antagonists does not lead
to detectable a nuclear signaling enhancement, as measured
as histone H3 phosphorylation. However, the assessment of a
potential positivemodulatory effect of glutamate andD1 receptor
antagonists is technically challenging, considering that the dose
we had to use to elicit detectable pH3 in response to BDNF
(20 ng/ml) is already saturating, while the lower dose (10 ng/ml)
did not activate pH3 at all, due to the non-graded dose-response
for this marker.
An important additional consideration is related to the
cell specificity of the observed modulation. TrkB and NMDA
receptors are expressed in all mature MSNs, both in the direct
and the indirect striatal pathways, while D1Rs are largely
confined, in rodents, to the direct pathway. It is formally
possible that the observed enhancement of BDNF-mediated
ERK activation produced by the blockade of glutamate and
D1 receptors occurs not in the dMSNs, where all three
receptors are expressed, but rather in the MSNs of the indirect
pathway (iMSNs). Alternatively, the observed enhancement of
BDNF-mediated ERK phosphorylation may occur in dMSNs as a
compensatory mechanism when the D1 and glutamate receptors
activity is compromised. We currently have no clear hypothesis
to explain this observation.
The complementary (and converse) experiment in Figure 6
aimed at determining whether TrkB receptors may modulate,
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directly or indirectly, D1 and glutamate receptors. The result,
i.e., TrkB inhibition with cyclotraxin B attenuates both glutamate
and SKF38393 ability to activate ERK signaling in MSNs,
is certainly more in line with previous evidence indicating
that BDNF signaling contributes to both dopamine and
glutamate signaling.
The existence of cooperation between glutamate and BDNF
is supported by an increasing number of studies. In this
regard, it has been shown that BDNF enhances excitatory
synaptic transmission in the hippocampus through pre- and
post-synaptic mechanisms by enhancing glutamate release and
regulating the expression, trafficking, and activity of both AMPA
and NMDA receptors. For instance, in cultured hippocampal
neurons activation of TrkB receptors by BDNF increases
the delivery of NMDA receptors to the plasma membrane
as well as the expression of the AMPAR subunits GluR1,
GluR2, and GluR3 (Caldeira et al., 2007a,b). Interestingly, it
has also been shown that BDNF-induced dendritic growth
is mediated by ERK and requires both BDNF-induced
CREB phosphorylation and the nuclear translocation of
CREB-regulated transcription coactivator (CRTC1), triggered
by NMDA receptors (Finsterwald et al., 2010). Similarly,
signal integration mechanisms between BDNF and dopamine
D1 receptors do also exist. For instance, in the hippocampus,
dopamine-mediated persistence of long-term memory seems to
be mediated by BDNF (Rossato et al., 2009). Furthermore, in
the basolateral amygdala the threshold for LTP induction, which
may be critically involved in the acquisition and consolidation of
fear memory, is strictly dependent on the concurrent activation
of postsynaptic D1 and TrkB receptors (Li et al., 2011).
Finally, the best indirect evidence available at the functional
level in the striatum is the negative effect of TrkB inhibitors
on acute amphetamine-dependent behavior (McGinty
et al., 2010). However, once again, that effect seems rather
indirect since amphetamine was able to increase TrkB
phosphorylation only in a delayed manner, around 3 h
post-injection, while ERK activation is already maximal as early
as 15 min in response to psychostimulants (Valjent et al., 2005;
Shi and McGinty, 2007).
Overall, our results support an unprecedented complexity in
the crosstalk among glutamatergic, dopaminergic, and BDNF
signaling converging onto the ERK pathway in the striatum.
To be noted, our studies have been carried out only in male
subjects so far. Further investigations will be necessary to clarify
the biochemical details of how these signals integrate into the
basal ganglia circuitry to modulate behavioral plasticity, also
concerning possible sex differences.
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